Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2011

01.11.2011 | Retinal Disorders

The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)

verfasst von: Khaled Nassar, Julia Lüke, Matthias Lüke, Mahmoud Kamal, Effat Abd El-Nabi, Mahmoud Soliman, Martin Rohrbach, Salvatore Grisanti

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The cytokine transforming growth factor-ß (TGF-ß) is a pivotal contributor to tissue fibrosis and a key cytokine in the pathogenesis of cellular transdifferentiation, epithelial-mesenchymal transition (EMT), and cell adhesion. This study evaluates the effect of decorin, a naturally occurring TGF-ß inhibitor, in an experimental rabbit model for proliferative vitreoretinopathy (PVR).

Methods

Traumatic PVR was induced in 50 rabbits divided into ten groups (n = 5). One group (GI) reveals a control with no treatment after trauma. Groups (GII–GIV) consisted of subgroups receiving phacovitrectomy at three different time points; (a) at the time of trauma, (b) 1 week following trauma, and (c) 2 weeks following trauma. GIII and GIV received 100 μg or 200 μg decorin, respectively. PVR severity was scored from 0 to 4. The amount of fibrosis was quantified using JMicroVision© software.

Results

The control group GI developed severe PVR with tractional retinal detachment (TRD); (PVR score ≥2) in four rabbits out of five. Vitrectomy had a positive effect (p < 0.05) on PVR development when preformed immediately, however the developed fibrosis was high. The best results were obtained when surgery was used in conjunction with decorin that reduced both the PVR score and fibrosis development significantly (p < 0.05). Depending on dosage and time of vitrectomy, PVR could be completely avoided (PVR score = 0) in 16 rabbits out of 30. TRD was prevented in 13 rabbits out of 15 in GIII to 14 rabbits out of 15 in GIV. In decorin-treated eyes, vitrectomy outcome was best when preformed at 1 week after trauma. There were no drug-related toxic effects evident on clinical and histopathological examination.

Conclusions

In conclusion, in this rabbit model of PVR, adjuvant decorin application during vitrectomy effectively reduces fibrosis and TRD development. In conjunction with no obvious histopathological toxicity signs, decorin represents a promising substance to inhibit PVR reactions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Tanihara H, Inatani M, Koga T, Yano T, Kimura A (2002) Proteoglycans in the eye. Cornea 21:S62–S69PubMedCrossRef Tanihara H, Inatani M, Koga T, Yano T, Kimura A (2002) Proteoglycans in the eye. Cornea 21:S62–S69PubMedCrossRef
2.
Zurück zum Zitat Hagedorn M, Esser P, Wiedemann P, Heimann K (1993) Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ger J Ophthalmol 2:28–31PubMed Hagedorn M, Esser P, Wiedemann P, Heimann K (1993) Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ger J Ophthalmol 2:28–31PubMed
3.
Zurück zum Zitat Iozzo R (1999) The biology of the small leucine-rich proteoglycan. J Biol Chem 27:18843–18846CrossRef Iozzo R (1999) The biology of the small leucine-rich proteoglycan. J Biol Chem 27:18843–18846CrossRef
4.
Zurück zum Zitat Vogel KG, Paulsson M, Heinegard D (1984) Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 223:587–597PubMed Vogel KG, Paulsson M, Heinegard D (1984) Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 223:587–597PubMed
5.
Zurück zum Zitat Fleischmajer R, Fisher LW, MacDonald ED, Jacobs L Jr, Perlish JS, Termine JD (1991) Decorin interacts with fibrillar collagen of embryonic and adult human skin. J Struct Biol 106:82–90PubMedCrossRef Fleischmajer R, Fisher LW, MacDonald ED, Jacobs L Jr, Perlish JS, Termine JD (1991) Decorin interacts with fibrillar collagen of embryonic and adult human skin. J Struct Biol 106:82–90PubMedCrossRef
6.
Zurück zum Zitat Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, Hook M (1992) Binding of the proteoglycan decorin to collagen type VI. J Biol Chem 267:5250–5256PubMed Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, Hook M (1992) Binding of the proteoglycan decorin to collagen type VI. J Biol Chem 267:5250–5256PubMed
7.
Zurück zum Zitat Winnemoller M, Schon P, Vischer P, Kresse H (1992) Interactions between thrombospondin and the small proteoglycan decorin: interference with cell attachment. Eur J Cell Biol 59:47–55PubMed Winnemoller M, Schon P, Vischer P, Kresse H (1992) Interactions between thrombospondin and the small proteoglycan decorin: interference with cell attachment. Eur J Cell Biol 59:47–55PubMed
8.
Zurück zum Zitat Lewandowska K, Choi HU, Rosenberg LC, Zardi L, Culp LA (1987) Fibronectin-mediated adhesion of fibroblasts: inhibition by dermatan sulfate proteoglycan and evidence for a cryptic glycosaminoglycan-binding domain. J Cell Biol 105:1443–1454PubMedCrossRef Lewandowska K, Choi HU, Rosenberg LC, Zardi L, Culp LA (1987) Fibronectin-mediated adhesion of fibroblasts: inhibition by dermatan sulfate proteoglycan and evidence for a cryptic glycosaminoglycan-binding domain. J Cell Biol 105:1443–1454PubMedCrossRef
9.
Zurück zum Zitat Schmidt G, Robenek H, Harrach B, Glössl J, Nolte V, Hörmann H, Richter H, Kresse H (1987) Interaction of small dermatan sulfate proteoglycan from fibroblasts with fibronectin. J Cell Biol 104:1683–1691PubMedCrossRef Schmidt G, Robenek H, Harrach B, Glössl J, Nolte V, Hörmann H, Richter H, Kresse H (1987) Interaction of small dermatan sulfate proteoglycan from fibroblasts with fibronectin. J Cell Biol 104:1683–1691PubMedCrossRef
10.
Zurück zum Zitat Vogel KG, Trotter JA (1987) The effect of proteoglycans on the morphology of collagen fibrils formed in vitro. Coll Relat Res 7:105–114PubMed Vogel KG, Trotter JA (1987) The effect of proteoglycans on the morphology of collagen fibrils formed in vitro. Coll Relat Res 7:105–114PubMed
11.
Zurück zum Zitat Yamaguchi Y, Mann DM, Ruoslahti E (1990) Negative regulation of transforming growth factor- by the proteoglycan decorin. Nature 346:281–284PubMedCrossRef Yamaguchi Y, Mann DM, Ruoslahti E (1990) Negative regulation of transforming growth factor- by the proteoglycan decorin. Nature 346:281–284PubMedCrossRef
12.
Zurück zum Zitat Takeuchi Y, Kodama Y, Matsumoto T (1994) Bone matrix decorin binds transforming growth factor- and enhances its bioactivity. J Biol Chem 269:32634–32638PubMed Takeuchi Y, Kodama Y, Matsumoto T (1994) Bone matrix decorin binds transforming growth factor- and enhances its bioactivity. J Biol Chem 269:32634–32638PubMed
13.
Zurück zum Zitat Vial C, Gutierrez J, Santander C, Cabrera D, Brandan E (2011) Decorin interacts with CTGF/CCN2 through LRR12 inhibiting its biological activity. J Biol Chem 2011 Mar 23. [Epub ahead of print] Vial C, Gutierrez J, Santander C, Cabrera D, Brandan E (2011) Decorin interacts with CTGF/CCN2 through LRR12 inhibiting its biological activity. J Biol Chem 2011 Mar 23. [Epub ahead of print]
14.
Zurück zum Zitat Nili N, Cheema AN, Giordano FJ, Barolet AW, Babaei S, Hickey R, Eskandarian MR, Smeets M, Butany J, Pasterkamp G, Strauss BH (2003) Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function. Am J Pathol 163:869–878PubMedCrossRef Nili N, Cheema AN, Giordano FJ, Barolet AW, Babaei S, Hickey R, Eskandarian MR, Smeets M, Butany J, Pasterkamp G, Strauss BH (2003) Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function. Am J Pathol 163:869–878PubMedCrossRef
15.
Zurück zum Zitat Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV (1998) Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101:406–412PubMedCrossRef Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV (1998) Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101:406–412PubMedCrossRef
16.
Zurück zum Zitat Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274:4489–4493PubMedCrossRef Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274:4489–4493PubMedCrossRef
17.
Zurück zum Zitat Patel S, Santra M, McQuillan DJ, Iozzo RV, Thomas AP (1998) Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells. J Biol Chem 273:3121–3124PubMedCrossRef Patel S, Santra M, McQuillan DJ, Iozzo RV, Thomas AP (1998) Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells. J Biol Chem 273:3121–3124PubMedCrossRef
18.
Zurück zum Zitat Hausser H, Wedekind P, Sperber T, Peters R, Hasilik A, Kresse H (1996) Isolation and cellular localization of the decorin endocytosis receptor. Eur J Cell Biol 71:325–331PubMed Hausser H, Wedekind P, Sperber T, Peters R, Hasilik A, Kresse H (1996) Isolation and cellular localization of the decorin endocytosis receptor. Eur J Cell Biol 71:325–331PubMed
19.
Zurück zum Zitat Rachal WF, Burton TC (1979) Changing concepts of failure after retinal detachment surgery. Arch Ophthalmol 97:480–483PubMed Rachal WF, Burton TC (1979) Changing concepts of failure after retinal detachment surgery. Arch Ophthalmol 97:480–483PubMed
20.
Zurück zum Zitat Kauffmann DJ, van Meurs JC, Mertens DA, Peperkamp E, Master C, Gerritsen ME (1994) Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sic 35:900–906 Kauffmann DJ, van Meurs JC, Mertens DA, Peperkamp E, Master C, Gerritsen ME (1994) Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sic 35:900–906
21.
Zurück zum Zitat Limb GA, Little BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Dumonde DC (1991) Cytokines in proliferative vitreoretinopathy. Eye 5:686–693PubMedCrossRef Limb GA, Little BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Dumonde DC (1991) Cytokines in proliferative vitreoretinopathy. Eye 5:686–693PubMedCrossRef
22.
Zurück zum Zitat Casaroli-Marano RP, Pagan R, Vilaró S (1999) Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 40:2062–2072PubMed Casaroli-Marano RP, Pagan R, Vilaró S (1999) Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 40:2062–2072PubMed
23.
Zurück zum Zitat Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784PubMed Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784PubMed
24.
Zurück zum Zitat Bornstein P (2001) Thrombospondins as matricellular modulators of cell function. J Clin Invest 107:929–934PubMedCrossRef Bornstein P (2001) Thrombospondins as matricellular modulators of cell function. J Clin Invest 107:929–934PubMedCrossRef
25.
Zurück zum Zitat Shah M, Foreman DM, Ferguson MW (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sic 108:985–1002 Shah M, Foreman DM, Ferguson MW (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sic 108:985–1002
26.
Zurück zum Zitat Cordeiro MF, Gay JA, Khaw PT (1999) Human anti-transforming growth factor-2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 40:2225–2234PubMed Cordeiro MF, Gay JA, Khaw PT (1999) Human anti-transforming growth factor-2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 40:2225–2234PubMed
27.
Zurück zum Zitat Siriwardena D, Khaw PT, King AJ (2002) Human antitransforming growth factor beta (2) monoclonal antibody, a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 190:427–431CrossRef Siriwardena D, Khaw PT, King AJ (2002) Human antitransforming growth factor beta (2) monoclonal antibody, a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 190:427–431CrossRef
28.
Zurück zum Zitat Grisanti S, Szurman P, Warga M, Kaczmarek R, Ziemssen F, Tatar O, Bartz-Schmidt KU (2005) Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 46:191–196PubMedCrossRef Grisanti S, Szurman P, Warga M, Kaczmarek R, Ziemssen F, Tatar O, Bartz-Schmidt KU (2005) Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 46:191–196PubMedCrossRef
29.
Zurück zum Zitat Cleary PE, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rabbit I. Method of production and natural history. Br J Ophthalmol 63:306–311PubMedCrossRef Cleary PE, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rabbit I. Method of production and natural history. Br J Ophthalmol 63:306–311PubMedCrossRef
30.
Zurück zum Zitat Hsu HT, Ryan SJ (1986) Natural history of penetrating ocular injury with retinal laceration in the monkey. Graefes Arch Clin Exp Ophthalmol 224:1–6PubMedCrossRef Hsu HT, Ryan SJ (1986) Natural history of penetrating ocular injury with retinal laceration in the monkey. Graefes Arch Clin Exp Ophthalmol 224:1–6PubMedCrossRef
31.
Zurück zum Zitat Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR (2007) In vivo models of proliferative vitreoretinopathy. Nat Protoc 2:67–77PubMedCrossRef Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR (2007) In vivo models of proliferative vitreoretinopathy. Nat Protoc 2:67–77PubMedCrossRef
32.
Zurück zum Zitat Vergara O, Ogden T, Ryan SJ (1989) Posterior penetrating injury to the rabbit eye: effect of blood and ferrous ions. Exp Eye Res 49:1115–1126PubMedCrossRef Vergara O, Ogden T, Ryan SJ (1989) Posterior penetrating injury to the rabbit eye: effect of blood and ferrous ions. Exp Eye Res 49:1115–1126PubMedCrossRef
33.
Zurück zum Zitat Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, Cui JZ, Kimura H, Hinton DR, Ryan SJ (1997) Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 104:1166–1173PubMed Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, Cui JZ, Kimura H, Hinton DR, Ryan SJ (1997) Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 104:1166–1173PubMed
34.
Zurück zum Zitat Sehu W, Lee W (2005) Ophthalmic pathology: an illustrated guide for clinicians. Blackwell Publishing Ltd, Massachusetts Sehu W, Lee W (2005) Ophthalmic pathology: an illustrated guide for clinicians. Blackwell Publishing Ltd, Massachusetts
35.
Zurück zum Zitat Cardillo JA, Farah ME, Mitre J, Morales PH, Costa RA, Melo LA, Kuppermann B, Jorge R, Ashton P (2004) An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 88:1201–1205PubMedCrossRef Cardillo JA, Farah ME, Mitre J, Morales PH, Costa RA, Melo LA, Kuppermann B, Jorge R, Ashton P (2004) An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 88:1201–1205PubMedCrossRef
36.
37.
Zurück zum Zitat Charteris DG (1995) Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 79:953–960PubMedCrossRef Charteris DG (1995) Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 79:953–960PubMedCrossRef
38.
Zurück zum Zitat Ryan SJ (1985) The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 100:188–193PubMed Ryan SJ (1985) The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 100:188–193PubMed
39.
Zurück zum Zitat Kolb M, Margetts PJ, Sime PJ, Gauldie J (2001) Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 280:L1327–L1334PubMed Kolb M, Margetts PJ, Sime PJ, Gauldie J (2001) Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 280:L1327–L1334PubMed
40.
Zurück zum Zitat Ständer M, Naumann U, Wick W, Weller M (1999) Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 296:221–227PubMedCrossRef Ständer M, Naumann U, Wick W, Weller M (1999) Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 296:221–227PubMedCrossRef
41.
Zurück zum Zitat Merle B, Malaval L, Lawler J, Delmas P, Clezadin P (1997) Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Cell Biochem 67:75–83PubMedCrossRef Merle B, Malaval L, Lawler J, Delmas P, Clezadin P (1997) Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Cell Biochem 67:75–83PubMedCrossRef
42.
Zurück zum Zitat Merle B, Durussel L, Delmas PD, Clezardin P (1999) Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J Cell Biochem 75:538–546PubMedCrossRef Merle B, Durussel L, Delmas PD, Clezardin P (1999) Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J Cell Biochem 75:538–546PubMedCrossRef
43.
Zurück zum Zitat Yamaguchi Y, Ruoslahti E (1988) Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336:244–246PubMedCrossRef Yamaguchi Y, Ruoslahti E (1988) Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336:244–246PubMedCrossRef
44.
Zurück zum Zitat De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV (1996) Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271:18961–18965PubMedCrossRef De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV (1996) Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271:18961–18965PubMedCrossRef
45.
Zurück zum Zitat Isaka Y, Brees D, Ikegaya K, Kaneda Y, Imai E, Noble N (1996) Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2:418–423PubMedCrossRef Isaka Y, Brees D, Ikegaya K, Kaneda Y, Imai E, Noble N (1996) Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2:418–423PubMedCrossRef
46.
Zurück zum Zitat Giri S, Hyde D, Braun R, Gaarde W (1997) Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 54:1205–1217PubMedCrossRef Giri S, Hyde D, Braun R, Gaarde W (1997) Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 54:1205–1217PubMedCrossRef
47.
Zurück zum Zitat Logan A, Baird A, Berry M (1999) Decorin attenuates gliotic scar formation in the rat cerebral hemisphere. Exp Neurol 159:504–510PubMedCrossRef Logan A, Baird A, Berry M (1999) Decorin attenuates gliotic scar formation in the rat cerebral hemisphere. Exp Neurol 159:504–510PubMedCrossRef
48.
Zurück zum Zitat Fukushima K, Badlani N, Usas A, Riano F, Fu F, Huard J (2001) The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 29:394–402PubMed Fukushima K, Badlani N, Usas A, Riano F, Fu F, Huard J (2001) The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 29:394–402PubMed
49.
Zurück zum Zitat Mohan RR, Gupta R, Mehan MK, Cowden JW, Sinha S (2010) Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp Eye Re 91:238–245CrossRef Mohan RR, Gupta R, Mehan MK, Cowden JW, Sinha S (2010) Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp Eye Re 91:238–245CrossRef
50.
Zurück zum Zitat Cleary PE, Larus G, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rhesus monkey: vitreous-lens admixture. Br J Ophthalmol 64:801–808CrossRef Cleary PE, Larus G, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rhesus monkey: vitreous-lens admixture. Br J Ophthalmol 64:801–808CrossRef
51.
Zurück zum Zitat Cleary PE, Ryan SJ (1981) Vitrectomy in penetrating eye injury. Results of a controlled trial of vitrectomy in an experimental posterior penetrating eye injury in the rhesus monkey. Arch Ophthalmol 99:287–292PubMed Cleary PE, Ryan SJ (1981) Vitrectomy in penetrating eye injury. Results of a controlled trial of vitrectomy in an experimental posterior penetrating eye injury in the rhesus monkey. Arch Ophthalmol 99:287–292PubMed
52.
Zurück zum Zitat Cleary PE, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rabbit II. Histology of wound, vitreous, and retina. Br J Ophthalmol 63:312–321PubMedCrossRef Cleary PE, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rabbit II. Histology of wound, vitreous, and retina. Br J Ophthalmol 63:312–321PubMedCrossRef
53.
Zurück zum Zitat Hsu HT, Ryan SJ (1986) Experimental retinal detachment in the rabbit. Penetrating ocular injury with retinal laceration. Retina 6:66–69PubMedCrossRef Hsu HT, Ryan SJ (1986) Experimental retinal detachment in the rabbit. Penetrating ocular injury with retinal laceration. Retina 6:66–69PubMedCrossRef
54.
Zurück zum Zitat Margo CE, Lee A (1995) Fixation of whole eyes: the role of fixative osmolarity in the production of tissue artifact. Graefe's Arch Clin Exp Ophthalmol 233:366–370CrossRef Margo CE, Lee A (1995) Fixation of whole eyes: the role of fixative osmolarity in the production of tissue artifact. Graefe's Arch Clin Exp Ophthalmol 233:366–370CrossRef
55.
Zurück zum Zitat Blumenkranz MS, Ophir A, Clafiin AJ, Kajek A (1982) Fluorouracil for the treatment of massive preretinal proliferation. Am J Ophthalmol 94:458–467PubMed Blumenkranz MS, Ophir A, Clafiin AJ, Kajek A (1982) Fluorouracil for the treatment of massive preretinal proliferation. Am J Ophthalmol 94:458–467PubMed
56.
Zurück zum Zitat Fastenberg DM, Diddie KR, Sorgente N, Ryan SJ (1982) A comparison of different cellular innocula in an experimental model of massive periretinal proliferation. Am J Ophthalmol 93:559–564PubMed Fastenberg DM, Diddie KR, Sorgente N, Ryan SJ (1982) A comparison of different cellular innocula in an experimental model of massive periretinal proliferation. Am J Ophthalmol 93:559–564PubMed
57.
Zurück zum Zitat Fastenberg DM, Diddie KR, Dorey K, Ryan SJ (1982) The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am J Ophthalmol 93:565–572PubMed Fastenberg DM, Diddie KR, Dorey K, Ryan SJ (1982) The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am J Ophthalmol 93:565–572PubMed
58.
Zurück zum Zitat Hida T, Chandler DB, Sheta SM (1987) Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye. Graefes Arch Clin Exp Ophthalmol 225:303–307PubMedCrossRef Hida T, Chandler DB, Sheta SM (1987) Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye. Graefes Arch Clin Exp Ophthalmol 225:303–307PubMedCrossRef
59.
Zurück zum Zitat Au Eong KG, Kent D, Pieramici DJ (2002) Section III Mechanical globe injuries, chapter 23 vitreous and retina. In: Kuhn F, Pieramici DJ (eds) Ocular trauma principles and practice. Thieme Medical Publishers, New York, p 224 Au Eong KG, Kent D, Pieramici DJ (2002) Section III Mechanical globe injuries, chapter 23 vitreous and retina. In: Kuhn F, Pieramici DJ (eds) Ocular trauma principles and practice. Thieme Medical Publishers, New York, p 224
60.
Zurück zum Zitat Mittra RA, Mieler WF (1999) Controversies in the management of open-globe injuries involving the posterior segment. Surv Ophthalmol 44:215–225PubMedCrossRef Mittra RA, Mieler WF (1999) Controversies in the management of open-globe injuries involving the posterior segment. Surv Ophthalmol 44:215–225PubMedCrossRef
61.
Zurück zum Zitat Spalding SC, Sternberg P Jr (1990) Controversies in the management of posterior segment ocular trauma. Retina 10(Suppl 1):S76–S82PubMed Spalding SC, Sternberg P Jr (1990) Controversies in the management of posterior segment ocular trauma. Retina 10(Suppl 1):S76–S82PubMed
62.
Zurück zum Zitat Wang NK, Chen YP, Yeung L, Chen KJ, Chao AN, Kuo YH, Lee JS, Lai CC (2007) Traumatic pediatric retinal detachment following open globe injury. Ophthalmologica 221:255–263PubMedCrossRef Wang NK, Chen YP, Yeung L, Chen KJ, Chao AN, Kuo YH, Lee JS, Lai CC (2007) Traumatic pediatric retinal detachment following open globe injury. Ophthalmologica 221:255–263PubMedCrossRef
63.
Zurück zum Zitat Ashton P (2006) Retinal Drug Delivery. In: Jaffe JG, Ashton P, Pearson PA (eds) Intraocular drug delivery. Taylor and Francis Group, New York, pp 11–12 Ashton P (2006) Retinal Drug Delivery. In: Jaffe JG, Ashton P, Pearson PA (eds) Intraocular drug delivery. Taylor and Francis Group, New York, pp 11–12
64.
Zurück zum Zitat Girard P, Mimoun G, Karpouzas I, Montefiore G (1994) Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 14:417–424PubMedCrossRef Girard P, Mimoun G, Karpouzas I, Montefiore G (1994) Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 14:417–424PubMedCrossRef
65.
Zurück zum Zitat Nagasaki H, Shinagawa K (1995) Risk factors for proliferative vitreoretinopathy. Curr Opin Ophthalmol 6:70–75PubMedCrossRef Nagasaki H, Shinagawa K (1995) Risk factors for proliferative vitreoretinopathy. Curr Opin Ophthalmol 6:70–75PubMedCrossRef
66.
Zurück zum Zitat Mohan RR, Tovey JC, Gupta R, Sharma A, Tandon A (2011) Decorin biology, expression, function and therapy in the cornea. Curr Mol Med 11:110–128PubMed Mohan RR, Tovey JC, Gupta R, Sharma A, Tandon A (2011) Decorin biology, expression, function and therapy in the cornea. Curr Mol Med 11:110–128PubMed
67.
Zurück zum Zitat Meenakshi J, Vidyameenakshi S, Ananthram D, Ramakrishnan KM, Jayaraman V, Babu M (2009) Low decorin expression along with inherent activation of ERK1, 2 in ear lobe keloids. Burns 5:519–526CrossRef Meenakshi J, Vidyameenakshi S, Ananthram D, Ramakrishnan KM, Jayaraman V, Babu M (2009) Low decorin expression along with inherent activation of ERK1, 2 in ear lobe keloids. Burns 5:519–526CrossRef
Metadaten
Titel
The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)
verfasst von
Khaled Nassar
Julia Lüke
Matthias Lüke
Mahmoud Kamal
Effat Abd El-Nabi
Mahmoud Soliman
Martin Rohrbach
Salvatore Grisanti
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2011
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-011-1730-9

Weitere Artikel der Ausgabe 11/2011

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2011 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.